CCORF Maintains Penumbra(PEN.US) With Hold Rating, Maintains Target Price $374
Wells Fargo Maintains Penumbra(PEN.US) With Hold Rating, Maintains Target Price $374
Wells Fargo Remains a Hold on Penumbra (PEN)
RBC Capital Initiates Penumbra(PEN.US) With Hold Rating, Announces Target Price $374
RBC Capital Maintains Penumbra(PEN.US) With Hold Rating, Maintains Target Price $374
RBC Capital Sticks to Its Hold Rating for Penumbra (PEN)
Analysts Conflicted on These Healthcare Names: Irhythm Technologies (IRTC), Penumbra (PEN) and Evolus (EOLS)
RBC Capital Maintains Penumbra(PEN.US) With Hold Rating, Maintains Target Price $374
Penumbra (PEN) Receives a Hold From RBC Capital
Citi Maintains Penumbra(PEN.US) With Hold Rating, Maintains Target Price $350
Citi Sticks to Its Hold Rating for Penumbra (PEN)
Penumbra Is Maintained at Outperform by Evercore ISI Group
Evercore Maintains Penumbra(PEN.US) With Buy Rating, Cuts Target Price to $320
RBC Capital Maintains Penumbra(PEN.US) With Hold Rating, Maintains Target Price $374
Wells Fargo Maintains Penumbra(PEN.US) With Hold Rating, Maintains Target Price $374
CCORF Maintains Penumbra(PEN.US) With Hold Rating, Maintains Target Price $374
Canaccord Genuity Reaffirms Their Hold Rating on Penumbra (PEN)
Penumbra Is Maintained at Neutral by Citigroup
Penumbra Is Maintained at Outperform by Evercore ISI Group
RBC Capital Maintains Penumbra(PEN.US) With Hold Rating, Maintains Target Price $374